Earnings Feed
Start Free
TEVA PHARMACEUTICAL INDUSTRIES LTD·4

Mar 6, 4:08 PM ET

Kalif Eliyahu Sharon 4

Research Summary

AI-generated summary

Updated

Teva (TEVA) CFO Kalif Eliyahu Sharon Converts RSUs, Receives New RSU Grant

What Happened

  • Kalif Eliyahu Sharon, Chief Financial Officer of Teva Pharmaceutical Industries Ltd., had restricted share units (RSUs) vest and convert into ordinary shares on March 4, 2026, and received a new RSU grant the same day. Specifically, 33,512 RSUs (from a 2022 grant) and 23,251 RSUs (from a 2024 grant) were reported as converted/treated as exercised on 2026-03-04 (total converted = 56,763). A new grant of 53,175 RSUs was awarded on 2026-03-04.
  • The reported exercise/conversion entries show $0 or N/A for prices and the disposition entries are recorded at $0 — this reflects conversion/settlement of derivatives (no cash sale proceeds are shown). The Form 4 does not report a cash purchase or an open-market sale tied to these conversions.

Key Details

  • Transaction date: March 4, 2026 (all entries); Form 4 filed March 6, 2026 (timely filing).
  • Converted/vested RSUs: 33,512 and 23,251 (total 56,763). New RSU grant: 53,175.
  • Prices/values: Reported as $0 or N/A on the Form 4; no dollar proceeds were reported for the conversions.
  • Shares owned after transaction: Not provided in the data you supplied.
  • Notable footnotes:
    • F1: Ordinary shares may be represented by American Depositary Shares (each currently equals one ordinary share).
    • F2: Each RSU represents a contingent right to receive one ordinary share or, at the committee’s option, cash on settlement.
    • F3–F5: Describe the original grant dates and vesting schedules for the 2022, 2024 and 2026 grants referenced above.
  • Filing timeliness: Filed two days after the transactions (typical reporting window); no late filing flag indicated.

Context

  • RSU vesting/conversion and new RSU grants are compensation-related events, not open-market purchases or sales. Conversions recorded as derivative dispositions at $0 commonly reflect settlement of RSUs into shares (and sometimes tax withholding) rather than a cash sale; the filing shows no separate market sale of the converted shares.
  • For retail investors, awards and vesting indicate executive compensation activity but are not direct bullish/bearish trading signals.